HB712
Office-based buprenorphine treatment; Board of Medicine to amend regulations.
Status:
In Senate
Latest Action:
Feb. 3, 2026
Senate: Referred to Committee on Education and Health
Chief Patron:
Otto Wachsmann (R)
Session:
2026 Regular Session
Summary
As Introduced. Board of Medicine;
office-based buprenorphine treatment; counseling. Directs the Board of Medicine to amend its regulations regarding office-based buprenorphine treatment to require providers to offer counseling or referral to counseling to each patient as clinically necessary and mutually agreed-upon. The bill specifies that a patient's refusal of counseling does not preclude the patient ... (More) from receiving office-based buprenorphine treatment for opioid use disorder. This bill is a recommendation of the Joint Commission on Health Care. (Less)-
Bill History
- 01/13/2026 - House: Prefiled and ordered printed; Offered 01-14-2026 26104755D
- 01/13/2026 - House: Referred to Committee on Health and Human Services
- 01/16/2026 - House: Fiscal Impact Statement from Department of Planning and Budget (HB712)
- 01/21/2026 - House: Assigned sub: Health Professions
- 01/21/2026 - House: Placed on Health and Human Services Agenda
- 01/22/2026 - House: Subcommittee recommends reporting (10-Y 0-N)
- 01/26/2026 - House: Placed on Health and Human Services Agenda
- 01/27/2026 - House: Reported from Health and Human Services (22-Y 0-N)
- 01/29/2026 - House: Read first time
- 01/30/2026 - House: Read second time and engrossed
- 02/02/2026 - House: Read third time and passed House (99-Y 0-N 0-A)
- 02/03/2026 - Senate: Constitutional reading dispensed (on 1st reading)
- 02/03/2026 - Senate: Referred to Committee on Education and Health
